Ratings Waters Corporation Deutsche Boerse AG

Equities

WAZ

US9418481035

Market Closed - Deutsche Boerse AG Other stock markets 02:02:59 2024-05-22 am EDT			5-day change	1st Jan Change
320.7 ^EUR	-0.53%		-2.40%	+6.90%

May. 22	Deutsche Bank Adjusts Waters Price Target to $330 From $304	MT
May. 16	Waters Corp Insider Sold Shares Worth $1,446,560, According to a Recent SEC Filing	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.29 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
WATERS CORPORATION	+6.90%	20.86B	-
THERMO FISHER SCIENTIFIC	+11.31%	225B	B
DANAHER CORPORATION	+15.50%	197B	B-
INTUITIVE SURGICAL, INC.	+18.83%	143B	B-
BOSTON SCIENTIFIC CORPORATION	+30.38%	111B	A-
SIEMENS HEALTHINEERS AG	+2.62%	64.72B	A-
EDWARDS LIFESCIENCES CORPORATION	+18.31%	54.44B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.96%	51.06B	B+
AGILENT TECHNOLOGIES, INC.	+9.95%	45.03B	A
GE HEALTHCARE TECHNOLOGIES INC.	+4.27%	37.4B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes